In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 24, 2018. A Pharma Trade From Goldman Jayson Derrick outlines a bull and bear call on Catelent, Inc CTLT and Valeant Pharmaceuticals International, Inc VRX, respectively, from Goldman Sachs. Check out “Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant.” Puma Biotech Declawed By European Medicines Agency Puma Biotechnology, Inc PBYI shares were crushed Wednesday after reporting a negative trend vote from European regulators regarding its neratinib compound. Learn more in Shanthi Rexaline’s. SourceStochastics are overbought, the upside is over. $CTLT, Catalent, Inc. / D There is a breakout of the rising channel, some downside still holds. $BHC, Bausch Health Companies Inc. / D Some downside still holds, but, however, the price should go up sooner or later and close the gap. $PBYI, Puma Biotechnology Inc / D